Skip to main content

Roche named as the most future-ready pharma company

Roche Towers, headquarters of a big pharma company in the Basel Area
| News

Roche named as the most future-ready pharma company

26.11.2024

In terms of global pharmaceutical companies, Roche is the best prepared for the future. This is the result of the Future Readiness Indicator 2024 published by the IMD in Lausanne. Roche excels on account of its capacity for innovation, among other aspects. Novartis is also ranked among the frontrunners.

Roche Towers, headquarters of a big pharma company in the Basel Area
The two towers are the landmarks of the global Roche headquarters in Basel

In the view of the IMD, out of the globally active pharma companies Roche is the best prepared for the future. The Basel-based firm scored full marks of 100 points and therefore secured top spot in the Future Readiness Indicator 2024 compiled by the private business school based in Lausanne. Last year, Roche finished in fifth place with a score of just 82.3 points.

According to the analysts in Lausanne, Roche excels in the area of research and development, as well as through its ability to quickly implement innovations and its full product pipeline. Roche achieved a score of 100 points across all three subcategories, with the IMD additionally reserving praise for the diversification of the company’s product portfolio.

Also Novartis among the best

With a score of 93.2 points, Novartis also ranks among the leading lights of the top five most future-ready companies. This represents an improvement on its score of 85.4 points last year. The company impressed in particular with the diversification of its business portfolio. Howard Yu highlights the importance of diversification for the future readiness of pharmaceutical companies: “Given the uncertainties of scientific discovery and what will be the next moonshot, means that for pharmaceutical companies, having a broader portfolio is more important than ever before to hedge risk”, as the Director of the IMD Center for Future Readiness observed.

Both Roche and Novartis have moved to strengthen their business through acquisitions. For example, Roche agreed a takeover of the cell therapy company Poseida Therapeutics from San Diego, California, for a price of around 1.5 billion US dollars. The two firms had already been working together since 2022. For its part, Novartis acquired Kate Therapeutics, a gene therapy specialist also based in San Diego, at a cost of up to 1.1 billion US dollars.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.